|
COPYRIGHT 2005 International Medical News Group
One of the hottest recent treatment advances in oncology has spawned an unwelcome dermatologic side effect.
Signal transduction inhibitors, a new class of cancer drugs targeting solid tumors without the toxic side effects of chemotherapy, are causing treatment-resistant folliculitis in up to 75% of patients.
"We've been trying, but we haven't hit on a successful treatment yet," said Peter Heald, M.D., professor of dermatology at Yale University, New Haven, who has begun to see several of these folliculitis patients. "They get better, but if you are talking about clearing--never.
"And we are talking about long courses of treatment with these [cancerl drugs," he added.
Signal transduction inhibitors--also known as tyrosine kinase inhibitors--target rogue kinases...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
